Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, is in the business of acquiring, developing and commercializing prescription products for hospital acute care, gastroenterology, and oncology both in the United States and internationally. Their lineup includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, and Vibativ, an injection that treats various bacterial infections. The company has also developed RediTrex, which is used to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. Ifetroban, a product candidate that is in the phase II clinical trial, is in development for the treatment of various diseases such as aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy. The company has already completed the phase II clinical trial of ifetroban for the treatment of hepatorenal syndrome and portal hypertension. Ifetroban is also being studied as a clinical program for treating progressive fibrosing interstitial lung diseases, whereas another candidate can soon work as a cholesterol-reducing agent in the hospital setting. The company, established in 1999, is a major player in the industry and focuses on the commercialization and improvement of healthcare.
Cumberland Pharmaceuticals Inc's ticker is CPIX
The company's shares trade on the NASDAQ stock exchange
They are based in Nashville, Tennessee
There are 51-200 employees working at Cumberland Pharmaceuticals Inc
It is cumberlandpharma.com
Cumberland Pharmaceuticals Inc is in the Healthcare sector
Cumberland Pharmaceuticals Inc is in the Drug Manufacturers - Other industry
The following five companies are Cumberland Pharmaceuticals Inc's industry peers: